Page last updated: 2024-11-01

nevirapine and Cardiometabolic Syndrome

nevirapine has been researched along with Cardiometabolic Syndrome in 2 studies

Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.

Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.

Research Excerpts

ExcerptRelevanceReference
" These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice."2.43Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. ( Mallal, S; Nolan, D; Reiss, P, 2005)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nolan, D2
Reiss, P1
Mallal, S1

Reviews

2 reviews available for nevirapine and Cardiometabolic Syndrome

ArticleYear
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardi

2005
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
    Drug safety, 2005, Volume: 28, Issue:12

    Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infection

2005